[1]吴钒 李志钢△ 熊昌源 瞿浩 吕仙辉.补肾健骨汤治疗肝肾阴虚型骨质疏松症的临床对照研究[J].中国中医骨伤科杂志,2021,29(04):39-42.
　WU Fan LI Zhigang XIONG Changyuan QU Hao LYU Xianhui.A Single-Center Case-Control Study of Bushen Jiangu Decoction inthe Treatment of Osteoporosis of Liver and Kidney Yin Deficiency[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2021,29(04):39-42.
点击复制

补肾健骨汤治疗肝肾阴虚型骨质疏松症的临床对照研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第29卷
期数:
2021年04期
页码:
39-42
栏目:
临床研究
出版日期:
2021-04-15

文章信息/Info

Title:
A Single-Center Case-Control Study of Bushen Jiangu Decoction inthe Treatment of Osteoporosis of Liver and Kidney Yin Deficiency
文章编号:
1005-0205(2021)04-0039-04
作者:
吴钒1 李志钢1△ 熊昌源2 瞿浩1 吕仙辉1
1湖北省中西医结合医院/湖北中医药大学附属新华医院(武汉,430015)
2湖北省中医院/湖北中医药大学附属医院
Author(s):
WU Fan1 LI Zhigang1△ XIONG Changyuan2 QU Hao1 LYU Xianhui1
1Department of Orthopedics,Hubei Provincial Hospital of Integrated Chinese &Western Medicine,Wuhan 430015,China; 2Department of Orthopedics,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China.
关键词:
骨质疏松症;  补肾健骨汤;  对照研究;  肝肾阴虚型
Keywords:
osteoporosis;  Bushen Jiangu decoction;  single-center case-control study;  liver and kidney yin deficiency
分类号:
R274.39
文献标志码:
A
摘要:
目的:通过临床单中心病例对照研究,观察补肾健骨汤治疗肝肾阴虚型骨质疏松症的临床疗效及安全性。方法:通过单中心病例注册软件将我科骨质疏松椎体骨折PKP术后复诊患者进行病例注册登记,选择符合诊断为肝肾阴虚型骨质疏松症的患者共90例纳入本研究; 依据患者接受中医药治疗方案分为对照组(A组,50例)与实验组(B组,40例)。对照组予以常规抗骨质疏松治疗,观察组在对照组的基础上加用补肾健骨汤治疗。两组均连续治疗3个月,3个月后采用序惯治疗。至少随访6个月,比较两组治疗前后VAS评分、Oswestry 功能指数(ODI); 测定两组治疗前后骨密度值、椎体高度值及再骨折的发生率等,评价临床效果并进行统计学分析。结果:90例患者在治疗前年龄、性别、岁数、VAS评分、ODI、椎体高度等指标上无明显统计学差异。两组在治疗1、3、6个月VAS评分及ODI均较治疗前明显降低,且在治疗后3个月、6个月观察组优于对照组,差异有统计学意义(P<0.05)。观察组治疗后椎体高度丢失率优于对照组,差异有统计学意义(P<0.05)。治疗后6个月骨密度明显恢复,观察组骨密度恢复指标优于对照组,差异有统计学意义(P<0.05)。对照组总有效率84.0%,观察组总有效率97.5%,观察组疗效优于对照组(P<0.05)。观察组及对照组不良反应均轻微,差异无统计学意义(P>0.05)。结论:与常规抗骨质疏松相比,补肾健骨汤在肝肾阴虚型骨质疏松症的抗骨质疏松效果显著,能够有效改善骨骼质量、减少椎体高度丢失,且用药安全、依从性好。
Abstract:
To evaluate the clinical efficacy of Bushen Jiangu decoction in treating osteoporosis of liver and kidney yin deficiency by single-center case-control study.Methods:A single-center case-control study was used to consecutively enroll 90 patients who underwent PKP/PVP of osteoporotic vertebral compression fractures.According to the combination medication,50 patients in treatment group A were gave calcium tablets,calcitriol capsules and salmon calcitonin combined with anti-osteoporosis treatment.40 patients in treatment group B were added Bushen Jiangu decoction on the basis of treatment group A.After the treatment of three months later,the patients were treated with routine therapy.The patients were followed up for at least 6 months.Visual analogue score(VAS)and oswestey dysfunction index(ODI)were documented.Bone mineral density,the height recovery of the vertebral body and adverse reactions were compared between the two groups.Results:There were no differences in preoperative among 90 patients.The VAS score and ODI in the first month,the third month and the sixth month after treatment were significantly lower than those before,and there was significant difference between the two groups after treatment at 3 months and 6 months(P<0.05).The height recovery of the vertebral body in the B group was obviously better than that of the A group(P<0.05).Bone mineral density recovered six month after treatment.The bone mineral density in the B group was significant better than that of the A group(P<0.05).Group A and group B were better than before treatment in the rate of clinical efficacy,while there was statistical significance(P<0.05)between group A and group B.As the drug adverse reactions,it was mild in all treatment group A and B,and the rate of drug adverse reactions was no statistically significance(P>0.05).Conclusion:Compared with conventional anti-osteoporosis,Bushen Jiangu decoction has significant effect in liver and kidney yin deficiency osteoporosis.

参考文献/References:

[1] CURRY S J,KRIST A H,OWENS D K,et al.Screening for osteoporosis to prevent fractures:US preventive services task force recommendation statement[J].The Journal of the American Medical Association,2018,319(24):2521-2531.
[2] CHEN G,ZHANG Z,LIU Y,et al.Efficacy and safety of Zuogui Pill in treating osteoporosis:study protocol of a systematic review[J].Medicine,2019,98(8):e13936.
[3] 李祥雨,姜劲挺,李建国,等.骨质疏松症中药防治研究进展[J].中国骨质疏松杂志,2018,24(2):270-275.
[4] 陈姣,梁繁荣.从循证医学角度思考针灸临床研究发展的机遇与挑战[J].中国循证医学杂志,2010,23(12):56-59.
[5] 刘保延.中医临床疗效评价研究的现状与展望[J].中国科学基金,2010(5):268-274.
[6] 蔡荣林,胡玲,吴子建.循证医学、真实世界研究在针灸临床研究中的应用与思考[J].中国针灸,2015,15(9):949-952.
[7] 中国老年学学会骨质疏松委员会中医药与骨病学科组.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015,21(9):1023-1028.
[8] 牛广续,刘振峰,王振斌,等.经皮椎体成形高黏度骨水泥注入修复老年椎体压缩骨折:椎体高度恢复评价[J].中国组织工程研究,2015,19(38):6126-6132.
[9] 国家食品药品监督管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:356-359.
[10] 吴钒,肖耀广,李志钢,等.中医正骨联合椎体后凸成形术治疗骨质疏松性椎体压缩性骨折的临床研究[J].中国中医骨伤科杂志,2018,26(8):30-33.
[11] ECK J C,NACHTIGALL D,HUMPHREYS S C,et al.Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures:a meta-analysis of the literature[J].The Spine Journal,2008,8(3):488-497.
[12] VENMANS A, KLAZEN C A, LOHLE P N,et al.Natural history of pain in patients with conservatively treated osteoporotic vertebral compression fractures:results from VERTOS Ⅱ[J].Am J Neuroradiol,2012,33(3):519-521.
[13] 雷宁波,彭冉东,邓强,等.依降钙素联合损伤胶囊对骨质疏松性椎体压缩骨折PKP术后早期临床疗效观察[J].中国中医骨伤科杂志,2017,25(5):9-12.
[14] 郑秀霞,林应华,黄雯晖,等.原发性骨质疏松症中医辨证分型研究[J].中医临床研究,2019,11(25):50-52.
[15] 马书娟,姚建平.补肾方药延缓衰老实验研究概况[J].世界中西医结合杂志,2012,7(8):721-724.
[16] 徐铮青,姚新苗,何帮剑,等.益骨汤加减治疗老年骨质疏松症的多中心随机对照临床研究[J].浙江中医药大学学报,2016,40(4):253-257.
[17] 张云飞,安军伟,龚幼波,等.原发性骨质疏松症的中医药防治研究进展[J].中国骨质疏松杂志,2019,25(4):554-558.

备注/Memo

备注/Memo:
基金项目:2019年湖北省中医药管理局青年人才项目(ZY2019Q020)
△通信作者 E-mail:20195200028@stu.gzucm.edu.cn
更新日期/Last Update: 2021-04-15